Considering the need for new, well tolerated and effective treatments to improve survival in metastatic NSCLC after platinum-based chemotherapy, Tumor Treating Fields (TTFields) therapy represents an innovative option. TTFields are electric fields that exert physical forces on electrically charged cellular components in dividing cancer cells, thus disrupting cell function.
cquired resistance to EGFR tyrosine kinase inhibitors (TKIs), even including the third-generation agent osimertinib, limits duration of response and survival in treated patients with EGFR-mutant lung tumors. A potential strategy to improve outcomes is the concomitant use of EGFR-targeted agents and platinum doublet chemotherapy, although EGFR TKI treatment might attenuate the effect of cytotoxic agents.
As is known, patients with extensive-stage small-cell lung cancer (ES-SCLC) tend to respond well to systemic induction therapy but frequently experience rapid disease progression. Subsequent treatment success remains a challenge; therefore, improving outcomes in the first line appears critical. Poly (ADP-ribose) polymerase (PARP) 1 has emerged as a potential therapeutic target in neuroendocrine tumors such as SCLC.
The randomized phase III ADAURA study was conducted in response to the unmet need of improving 5-year overall survival (OS) rates in patients with completely resected EGFR-mutated, stage IB-IIIA non-small cell lung cancer (NSCLC), which are estimated to range between 45 % and 85 %. In ADAURA, 682 patients after complete resection of stage IB, II, or IIIA NSCLC with or without adjuvant chemotherapy received either osimertinib 80 mg OD or placebo for 3 years.
Under this year’s motto “partnering with patients: the cornerstone of cancer care and research”, oncology experts from around the world gathered at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA, and virtually from 2nd–6th June 2023, to discuss the latest data in lung cancer with emphasis on practice-changing new studies, less toxic treatments, precision oncology and new ways to reduce collateral damage.
